Position in ARGX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,095,375
+$674,900 QoQ
Shares Held
1,500
+200.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
5 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ARGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026WEXFORD CAPITAL LP holds $5,121,968 across 6 Biotechnology names. ARGX ranks #1 (21.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
This page
|
1,500 | $1,095,375 | |
| 2 | TRVI |
Trevi Therapeutics, Inc.
|
90,752 | $1,082,671 | |
| 3 | SPRY |
ARS Pharmaceuticals, Inc.
|
130,313 | $1,046,413 | |
| 4 | TSHA |
Taysha Gene Therapies, Inc.
|
160,654 | $718,123 | |
| 5 | GPCR |
Structure Therapeutics Inc.
|
13,709 | $660,773 | |
| 6 | NUVB |
Nuvation Bio Inc.
|
120,889 | $518,613 |
All Filings in ARGX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,095,375 | 1,500 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $420,475 | 500 | Shares | Sole | 2026-02-13 | |
| 2025-06-30 | $275,610 | 500 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $887,797 | 1,500 | Shares | Sole | 2025-05-15 | |
| 2023-09-30 | $1,981,760 | 4,031 | Shares | Sole | 2023-11-14 | |
| No filing history on record for this holder in this stock. | ||||||